Biointron, a leading contract research organization (CRO) specializing in antibody discovery, optimization, and expression services, is proud to announce more than 2,500 biotech and pharmaceutical customers worldwide. This achievement underscores our trusted role in accelerating antibody research and development for life sciences innovators across the globe.
Founded in 2012, Biointron has built a strong reputation for speed, quality, and innovation in the antibody expression industry. To date, Biointron has delivered over 10,000 recombinant antibodies to partners around the world.
Hear It from Our Partners and Clients
We are proud to highlight the voices of those who have used our antibody services firsthand. From large biopharmaceutical organizations, emerging startups, and academic institutes, our partners and clients share how Biointron’s technical excellence, responsive collaboration, and innovative solutions have helped them achieve ambitious goals. Check out our Testimonials page!
Expanding Capabilities with New Platforms
In line with our commitment to innovation, we have recently introduced two advanced platforms:
- High-Throughput Fully Human Antibody Discovery Platform: Designed to accelerate the identification of fully human antibodies with exceptional diversity and specificity in 3 months, with our microfluidic platform AbDrop™ and Cyagen’s HUGO-Ab™ transgenic mice. Learn more >>
- ADC High-Throughput Antibody Conjugation Platform: Enabling high-quality, rapid antibody-drug conjugate (ADC) generation to support targeted therapeutic development. Learn more >>
These platforms further strengthen our ability to provide comprehensive, one-stop antibody solutions.
Special Offer for New Clients
To mark this milestone, we are offering 50% off services for new clients until December 31, 2025. This promotion applies to all of our antibody expression services, giving new partners an opportunity to experience Biointron’s speed, quality, and expertise at exceptional value. View full promotion details >>
About Biointron
Founded in 2012 and certified to ISO 9001:2015, Biointron is a CRO specializing in antibody discovery, expression, and optimization services for biotech and pharmaceutical companies.
Biointron holds a leading position in the antibody expression service industry. From gene sequence to purified antibodies, our production only takes 2 weeks. We have delivered tens of thousands of recombinant antibodies for more than 2,500 biotech and pharma companies worldwide. From gene sequence to purified antibodies, we deliver results in as little as two weeks, enabling research teams to move quickly from concept to discovery. For more information about Biointron’s services, visit www.biointron.com.